October 1, 2020 -- Johnson & Johnson has successfully completed its acquisition of Momenta Pharmaceuticals in an all-cash transaction for approximately $6.5 billion.
The acquisition was completed on October 1. Shares of Momenta were purchased by Johnson & Johnson's tender offer for $52.50 per share. As a result, Momenta's common stock will be delisted from the Nasdaq Global Select Market.
The acquisition will strengthen Johnson & Johnson's presence in the rare disease medicines space.